CBN has become a staple ingredient across both cannabis and hemp edible markets. This report combines five years of measured retail data from Headset Analytics with modeled extrapolation of the broader hemp and cannabis markets. The intent of this report is to shed light on a category that has quietly built into a billion-dollar sub-industry and to examine what its trajectory means for brands, buyers, and investors over the next five years.

This report covers the U.S. CBN market across four areas of analysis, with the heaviest weight on adult-use edible category analytics. Five years of point-of-sale data from Headset Analytics across 15 adult-use and medical-only markets form the foundation. That measured data is supplemented by demand evidence from consumer research, a sizing model that estimates the full U.S. CBN market across measured and unmeasured channels, and a forward outlook on where the category is heading through 2030.

Because there is no single source of measured sales data covering all U.S. CBN sales channels, the market sizing in this report is presented as a range, with full methodology disclosure on slide 23.

Five recent studies, surveying more than 200,000 people combined, highlight that dispensary consumers are shopping for benefits like sleep, pain relief, anxiety, and stress. The line between recreational use and wellness has effectively dissolved for the majority of the cannabis-buying population. Sleep benefits are clearly driving consumer buying decisions, particularly for ingestible products, but less so for inhalable products as demonstrated on slide 8. The evolution of cannabis products along side consumer education will almost certainly continue to support this trend.

The U.S. CBN market is roughly a billion-dollar subcategory in 2025, with CBN now accounting for nearly 19 percent of the regulated cannabis edibles category and a meaningful share of the broader hemp retail and medical-only state markets. The Headset Analytics retail panel measures CBN sales directly across 15 adult-use states. The remaining three channels — other adult-use states outside Headset, medical-only state markets, and the hemp-derived retail channel — are modeled using conservative assumptions that hold CBN's share below its measured 18.9 percent baseline in regulated cannabis. The hemp channel estimate is anchored on the Whitney Economics 2024 U.S. National Cannabinoid Report, which sizes total U.S. hemp-derived cannabinoid demand at $28 billion in 2024. Full methodology disclosure is documented on slide 23.

The analysis that follows in slides 8-18 is all built on retail point-of-sale data captured at licensed dispensaries across 15 legal recreational markets sourced from Headset analytics, which pulls sales records straight from dispensary cash registers rather than from surveys or brand reports.

CBN appears in five product categories tracked by Headset across 15 state regulated cannabis markets. Total CBN revenue across all of them grew from roughly $143 million in 2021 to about $519 million in 2025. Edibles dominate the mix — roughly 92% of CBN revenue in Q1 2026 came from edibles alone.

Edibles and tinctures have absorbed CBN most readily. Both formats are where consumers are familiar with buying for a specific functional outcome. Vapor pens, in contrast, never built a real CBN audience likely because the vapor pen consumer is purchasing on THC content as the main driver.

CBN's full-year growth rate inside a category, measured against that category's overall growth rate, shows whether the segment is outperforming the broader market. As categories mature and consumer preferences solidify, sales consolidate into fewer SKUs and the segments with validated demand pull ahead. The 2025 data shows that pattern: CBN edibles and tinctures are the formats consumers are choosing when they are looking for sleep solutions.

Above the line, CBN is outpacing its category. Below the line, it's a drag.

CBN's growth inside edibles demonstrates that this category is the most accessible for consumers who are seeking a specific benefit from their cannabis products. In Q1 2021, CBN accounted for $21 million in edible sales or roughly 5% of the category. By Q1 2026, that quarterly figure was $120 million, and CBN's share had climbed to nearly 19%.

The U.S. cannabis edible market reached an inflection point in 2024. After being reinvigorated through 2023 by new adult-use markets coming online — New Jersey, New York, Connecticut, Missouri, Maryland — category growth has now begun to plateau. The cannabis edible category is reshaping. Alongside other minor cannabinoid-infused products, CBN continues to show strong growth. Consumers are buying for outcomes — sleep, calm, recovery — and they are paying for formulations that deliver those outcomes. The growth inside the category is concentrated in products that pair THC with minor cannabinoids.

CBN has been leading that growth, and the trajectory has held across five years of measured retail data. This is what a category staple looks like in a maturing market. The brands building deeper CBN positions today are continuing to grow. The brands relying solely on THC-only formulations are likely watching their growth flatten alongside the broader category.

CBN products are on pace to capture 20.2 percent of the cannabis edible revenue in 2026, continuing the share-gain trajectory established over the past five years. CBN has gained an average of 2.8 percentage points of share growth annually since 2021, with the pace decelerating steadily from 3.5 points added in 2022 to 2.3 points in 2025. Applying that deceleration forward, with formulation improvements and consumer expansion partially offsetting the natural deceleration math, projects CBN to reach roughly 27 percent of recreational edibles by 2030. Most leading brands have CBN portfolios in market, so the next leg of growth will be driven by formulation improvements and consumer expansion rather than by a wave of new entrants.

The deceleration curve points to a ceiling somewhere between 30 and 33 percent of edibles. That ceiling represents the point where the remaining consumer base is structurally non-addressable for CBN. By 2030, CBN is projected to reach roughly 27 percent of recreational edibles in the base case, with upside scenarios pointing closer to 29 percent if formulation and channel expansion accelerate the curve.

CBN at functional dose is among the lowest-cost, highest-leverage formulation ingredients in cannabis edibles today. The category prices CBN-infused products at a 44% wholesale premium on roughly 12 cents of marginal ingredient cost — and that pricing power is sustained by genuine consumer demand. The proportional argument is simple: CBN ingredient cost is negligible relative to the wholesale premium it commands. Brands that recognize this and build deeper CBN portfolios systematically capture outsized margin on every unit sold.

Per 10-pack Margin Analysis

The brands that have built deliberate CBN portfolios are the same brands leading the category overall. Of the top 29 edible brands in the dataset, CBN is the #1 SKU for 12 of them. For the top eight brands by total revenue, CBN is a meaningful share of every brand's book. Wyld alone generated $115 million in CBN-attributable edible sales in 2025. Smokiez being the only top 8 brand where CBN is less than 17% of it's revenue.

Two years ago the dominant CBN edibles delivered 20mg–50mg of CBN per package paired with 100mg of THC. In the past two years, five leading brands have launched higher-dose, multi-cannabinoid SKUs — and in every case those products are outgrowing the older flagships they replaced.

Across five leading edible brands (Q1 2024 → Q1 2026), the relationship between dose and growth is not subtle. Older SKUs are contracting sharply while newer, higher-dose formulations are posting triple-digit gains.

A CBN gummy in Connecticut sells for $28.01 on average. The same kind of product in Michigan sells for $10.61. State-level dynamics — supply, number of license holders, market maturity, — drive nearly threefold variation in retail price for what is, broadly, the same kind of product.

The intuitive read on state-level pricing would be: more brands, more competition, lower prices. While that may be true for certian markets it is not the rule. New York has 69 distinct CBN edible brands competing — the most of any state — yet maintains the second highest average shelf price at $24.06. At the same time, California and Michigan which have the second and third largest number of brands are both toward or at the bottom.

The 28% projection on Slide 11 is built on the trend inside the 15 markets in this dataset. The forward picture becomes more optimistic if we account for regulatory changes that speed the implementation of new medical and adult-use markets.

This report has documented a billion-dollar CBN category built almost entirely inside regulated cannabis and hemp retail — but the next leg of growth lives outside those channels, among the consumers already shopping the supplement aisle for melatonin, magnesium, and alternative sleep aids. The mainstream supplement market reaches consumers cannabis and hemp brands cannot. TruCBN™ is the only CBN ingredient that has the safety and efficacy data to unlock hyper-growth with the supplement market.

The CBN category has reached the size, stability, and pricing power to support strategic investment from brands looking to capture new growth by converting current non-customers. Consumers are increasingly choosing cannabinoids as a wellness ingredient, and as cannabinoids continue to normalize, CBN will take an increasing share of the traditional sleep aid market.

The opportunity in cannabis and hemp is still expanding but the larger opportunity sits outside these channels in the mainstream nutraceutical and supplement market. The implications below are split into two sections: one for hemp and cannabis brands building deeper category positions today, and one for supplement and nutraceutical brands evaluating CBN as the next ingredient to enter the mainstream supplement channel.

FloraWorks is the developer and exclusive supplier of TruCBN™, and distributes CBN, CBG, THCV, and CBC to more than 100 cannabis and hemp brands across the United States. Our GMP and compliance documentation is built to industry-leading standards and is audit-ready for every state we operate in. Our minor cannabinoid portfolio lets brands consolidate their supply with a single trusted partner.,

This report covers CBN sales across U.S. cannabis markets from Q1 2021 through Q1 2026 — five years of point-of-sale data, supplemented by modeled extrapolation into adjacent channels where retail measurement is not available. The four channels below combine to size the full U.S. CBN market for decision-makers, formulators, retail buyers, and investors evaluating where the category is heading as a standalone sleep aid.